SymBio Pharmaceuticals Limited (SYMQY)
OTCMKTS · Delayed Price · Currency is USD
0.9577
-0.0299 (-3.03%)
Sep 19, 2025, 12:50 PM EDT
SymBio Pharmaceuticals Revenue
SymBio Pharmaceuticals had revenue of 381.98M JPY in the quarter ending June 30, 2025, a decrease of -44.40%. This brings the company's revenue in the last twelve months to 1.81B, down -50.91% year-over-year. In the year 2024, SymBio Pharmaceuticals had annual revenue of 2.45B, down -56.13%.
Revenue (ttm)
1.81B JPY
Revenue Growth
-50.91%
P/S Ratio
3.67
Revenue / Employee
16.80M JPY
Employees
108
Market Cap
46.16M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
Dec 31, 2020 | 2.99B | 149.30M | 5.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |